Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
5.70
Nov 17 • 3:59 PM ET Dollar change-0.81 Percentage change(-12.44%)
Aftermarket Close
5.70
Aftermarket • 6:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
13.05M
Enterprise Value
7.25M
Income
-29.38M
Sales
0.00M
Book/sh
7.66
Cash/sh
2.53
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
6
IPO
May 07, 2013
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.74
P/C
2.25
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.48
Current Ratio
0.48
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-8.84
EPS next Y
-5.49
EPS next Q
-2.23
EPS this Y
52.32%
EPS next Y
44.32%
EPS next 5Y
46.65%
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
79.47%
Sales Q/Q
-
Insider Own
0.40%
Insider Trans
0.00%
Inst Own
5.94%
Inst Trans
0.20%
ROA
-71.69%
ROE
-146.20%
ROIC
-167.85%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-26.40%
SMA50
-34.66%
SMA200
-35.79%
Trades
Shs Outstand
2.29M
Shs Float
2.28M
52W High
29.32 -80.56%
52W Low
3.02 89.05%
Volatility
12.30% 12.62%
ATR (14)
1.00
RSI (14)
36.50
Beta
1.51
Rel Volume
0.20
Avg Volume
61.60K
Volume
12,065
Perf Week
-20.06%
Perf Month
-42.37%
Perf Quarter
-27.85%
Perf Half Y
52.41%
Perf YTD
-50.69%
Perf Year
-69.91%
Perf 3Y
-95.55%
Perf 5Y
-99.57%
Perf 10Y
-99.91%
Prev Close
6.51
Price
5.70
Change %
-12.44%
Consensus
Strong Buy
Avg. Price Target
$25.50
Implied Upside
+347.4%
Analysts6incl. previous ratings
Rating Distribution4 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 20, 2026Upgrade
MMaxim Group
Hold → Buy$30+426.3%
Apr 08, 2026Downgrade
MMaxim Group
Buy → Hold
Jan 05, 2026Initiated
LLadenburg Thalmann
Buy$1-82.5%
Jul 18, 2025Initiated
MMaxim Group
Buy$5-12.3%
Jan 04, 2019Upgrade
BB. Riley FBR
Neutral → Buy$2.50 → $3-47.4%
Feb 08, 2018Initiated
BB. Riley FBR, Inc.
Neutral$3-47.4%
Sep 22, 2017Upgrade
WWilliam Blair
Mkt Perform → Outperform
May 31, 2017Upgrade
CChardan Capital Markets
Sell → Neutral$6+5.3%
Apr 17, 2017Reiterated
CChardan Capital Markets
Sell$6.50 → $5-12.3%
Jul 11, 2016Initiated
CChardan Capital Markets
Sell$5-12.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Sandip IDirectorOct 14 '26Option Exercise0.0010,052438,877Oct 16 05:20 PM
Bazemore Robert BDirectorOct 14 '26Option Exercise0.003,866222,759Oct 16 05:20 PM
Gaslightwala AbizerCEOOct 14 '26Option Exercise0.0027,0661141,173Oct 16 05:20 PM
Patel Samir RashmikantDirectorJul 07 '26Option Exercise0.4322,4749,68198,241Jul 17 06:03 AM
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.
CEOMr. Abizer Gaslightwala
Interim Chief Financial OfficerMr. Kameel D. Farag
Executive Director & Head of OncologyDr. Satyajit Mitra Ph.D.
Chief Business OfficerMr. Vatnak Vat-Ho M.B.A.